*Department of Laboratory Hematology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON
**Vancouver Costal Health
††Vancouver General Hospital/University of British Columbia, Vancouver, BC
##Department of Pathology, University of Calgary, Calgary, AB, Canada
†Canadian Immunohistochemistry Quality Control (CIQC), Vancouver, BC, Canada
‡Institute of Pathology, Aalborg University Hospital, Denmark
§Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark
∥Griffith University School of Medicine, Gold Coast Campus
¶Australian Institute for Bioengineering and Nano-Technology, University of Queensland, Qld, Australia
#Convenor Immunohistochemistry, Anatomical Pathology Program, RCPA QAP Pty Ltd., Sydney, Australia
‡‡Beth Israel Deaconess Medical Center
§§Brigham and Women’s Hospital, Harvard medical School, Boston, MA
∥∥UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK
¶¶University of Washington, Seattle, WA
***Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
†††Chinese Committee for Pathology-Immunohistochemistry Quality Control (CCP-IHCQC)
‡‡‡Keck School of Medicine, University of Southern California, Los Angeles, CA
E.E.T. and S.N. contributed equally.
Supported in part by the following NIH/NCI Grants and contracts: 1R33 CA-10345; HHSN261201200044C.
The authors declare no conflict of interest.
Reprints: Emina E. Torlakovic, MD, PhD, Department of Laboratory Hematology, Toronto General Hospital, University Health Network, University of Toronto, Pathology, 11th Floor, R411, 200 Elizabeth Street, Toronto, ON, Canada M5G 2C4 (e-mail: [email protected]).
Received October 31, 2014
Accepted November 1, 2014